Cartesian Therapeutics, Inc. (RNAC)
(Real Time Quote from BATS)
$36.79 USD
+2.07 (5.96%)
Updated Jun 3, 2024 12:33 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RNAC 36.79 +2.07(5.96%)
Will RNAC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNAC
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
Other News for RNAC
Buy Rating Affirmed on Cartesian Therapeutics’ DESCARTES-08 for Promising Myasthenia Gravis Treatment
Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning
Mizuho starts Cartesian at buy, cites lead drug asset
Cartesian Therapeutics initiated with bullish view at Mizuho, here's why
Wall Street Analysts Are Bullish on Top Healthcare Picks